Pharmaceutical Industry Articles & Reports - Page 3

A 2026 implementation guide to LOINC UCUM CDISC LB mapping, with a worked lab crosswalk, original and standard result fields, unit conversion checks, exception paths, and release governance.

A 2026 comparison of Posit, Domino, and SAS for pharma statistical computing, covering runtime control, package governance, validation evidence, batch execution, and phased coexistence.

A 2026 implementation guide mapping IEC 81001-5-1 activities to owners and evidence, with December 2025 corrections, IEC 62304 overlap, FDA submission mapping and lifecycle coverage calculations.

A 2026 architecture comparison of TetraScience, Scitara DLX, and Sapio covering instrument ingestion, scientific context, GxP boundaries, pricing evidence, export requirements, and a measurable proof of value.

A 2026 analysis of MHRA AI Airlock Phase 2's seven cases, mapping intended purpose, AI-IVD validation, PCCPs and post-market evidence to practical UK development and NHS deployment decisions.

A 2026 comparison of Opentrons Flex CRS and Tecan Fluent Gx covering intended use, Part 11 controls, audit trails, retention, qualification evidence, acceptance tests, and quote-normalized costs.

A 2026 guide to reconciling MAUDE, MDR files, openFDA and AEMS: report keys, supplemental updates, device mapping, source timing, and validation controls that preserve analytical lineage.

A 2026 guide to EMA's real-world data quality framework, covering its determinant hierarchy, 12 source-characterization areas, vendor evidence requests, metric calculations, and fitness-for-use decisions.

A 2026 guide to CDISC controlled terminology release management: semantic diffs, study version pinning, paired codelists, exception governance, and regression evidence, with a March 2026 worked example.

A 2026 buyer framework for Anthropic and Accenture AI evaluation in pharma: assurance layers, confidential evidence access, evaluator independence, change triggers, and procurement decisions.

A 2026 guide to Claude agents as code and ant apply for pharma, covering lockfile state, CI approval gates, drift, partial failures, workload identity, validation evidence, and recovery design.

A 2026 implementation reference for FHIR to OMOP mapping: resource and field crosswalks, terminology and time-precision loss, reconciliation metrics, and an analysis-specific validation and acceptance protocol.

A 2026 comparison of Spectronaut 21, DIA-NN, and PEAKS Online covering release channels, licensing, library strategies, benchmark limitations, and a matched pilot with QC metrics and cost calculations.

A 2026 guide to FDA PQ/CMC FHIR and ICH M16 readiness, with Stage 1 and Stage 2 profiles, source-system mappings, IDMP overlap, provenance controls, and validation criteria for structured Module 3 data.

A 2026 guide to DailyMed API v2 covering SET ID lineage, historical SPL downloads, pagination, identifier joins, Python retrieval, archive handling, and a reproducible label-change pipeline.

A 2026 analysis of Claude API on-demand compaction for pharma agents, covering signed blocks, current platform support, preserved thinking, critical-state regression tests, audit evidence, and measured token economics.

A 2026 implementation reference for CDISC ODM 2.0 migration, covering XML/JSON contracts, API evidence, backward compatibility, consumer matrices, validation tests, and archive preservation.

A 2026 comparison of Pinnacle 21, Nurocor and TCS ADD clinical metadata repositories, covering governance, CDISC coverage, study-build outputs, measured reuse, migration and a proof-of-concept script.

A 2026 data report on FDA PMR and PMC study status, original milestones, quarterly public-file limits, record identity, portfolio views, and an auditable tracking model.

A 2026 buyer guide to FlowJo 11, OMIQ, and Cytobank, with a matched-FCS pilot protocol, edition and licensing matrix, review controls, and a three-year cost worksheet.

A 2026 PMA eSTAR readiness guide covering the September draft, voluntary scope, designated supplements, version and attachment controls, center routing, screening, and a 30/60/90-day plan.

A 2026 guide to AccessGUDID API v3, record-key identity, version-aware schemas, daily and full-release ingestion, terminology enrichment, and reconciliation controls for medical device data.

2026 control matrix for Claude Managed Agents in GxP workflows: auto and always_ask outcomes, non-overridable denials, MCP versus custom tools, audit evidence, validation tests, and pilot metrics.

A 2026 antibody R&D comparison of Benchling Biologics, Genedata Biologics, and IDBS Polar across format modeling, registration, assay and sample lineage, interfaces, GxP, and a buyer-run proof of concept.